The HNRNPA0 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population offering a loss-of-function model for HNRNPA0 gene disruption. Derived from HeLa cells, this polyclonal pool provides a representative gene-edited population without the clonal selection bias inherent to monoclonal lines, ensuring robust performance in functional assays addressing post-transcriptional regulation in cancer and inflammation.
HeLa cells are an immortalized human epithelial cell line originally derived from a cervical adenocarcinoma, positive for human papillomavirus type 18 (HPV18). This widely used cancer model exhibits anchorage-independent growth and high transfectability, facilitating efficient CRISPR/Cas9 delivery. The oncogenic background of HeLa cells makes them particularly suitable for studying tumor cell biology, signal transduction, and therapeutic response mechanisms.
HNRNPA0 encodes an RNA-binding protein that specifically recognizes AU-rich elements (AREs) in the 3′ UTRs of mRNAs, controlling their stability and translation. Its function is regulated by stress-activated kinases, notably p38 MAPK, and cytokine signaling, linking extracellular stimuli to post-transcriptional gene expression. HNRNPA0 interacts with other RNA-binding proteins such as HuR, TTP, HNRNPA1, HNRNPA2B1, and SRSF1, and modulates the expression of downstream targets including TNF, COX2, and GM-CSF. Through these interactions, it participates in mRNA surveillance, RNA transport, and spliceosome-related processes, orchestrating the cellular transcriptome in response to environmental cues.
In the HeLa cervical cancer model, disruption of HNRNPA0 is expected to alter the stability of numerous ARE-containing transcripts, impacting processes such as inflammatory cytokine production, cell proliferation, and migration. Given the importance of ARE-mediated regulation in oncogenesis and immune cell function, this knockout cell population provides a valuable tool for dissecting HNRNPA0’s role in tumor biology, drug sensitivity, and stress adaptation. The HPV18-positive, immortalized background also permits investigation of viral-host interactions in RNA regulatory networks.
Research applications include quantitative analysis of mRNA decay via RT-qPCR, global transcriptomic profiling by RNA-seq, ARE-driven reporter assays, and functional assays such as migration, invasion, and drug sensitivity testing. Western blotting is recommended for knockout validation. This polyclonal model is well-suited for high-throughput screening where polyclonality reduces clone-specific artifacts. For further details, please contact Ascent Research.
